Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. SMA results from deletions or mutations of survival motor neuron 1 (SMN1), an essential gene. SMN2, a nearly identical copy, can compensate for SMN1 loss if SMN2 exon 7 skipping is prevented. Among the many cis-elements involved in the splicing regulation of SMN exon 7, intronic splicing silencer N1 (ISS-N1) has emerged as the most effective target for an antisense oligonucleotide (ASO)-mediated splicing correction of SMN2 exon 7. Blocking of ISS-N1 by an ASO has been shown to fully restore SMN2 exon 7 inclusion in SMA patient cells as well as in vivo. Here we review how ISS-N1 targeting ASOs that use different chemistries respond differently in the various SMA mouse models. We also compare other ASO-based strategies for therapeutic splicing correction in SMA. Given that substantial progress on ASO-based strategies to promote SMN2 exon 7 inclusion in SMA has been made, and that similar approaches in a growing number of genetic diseases are possible, this report has wide implications.
Introduction
Spinal muscular atrophy (SMA) is a leading neurodegenerative disease of children and infants [1] [2] [3] [4] [5] [6] [7] . SMA is characterized by the progressive loss of α-motor neurons in the spinal cord, which leads to paralysis of the trunk and limbs and respiratory insufficiency [2] [3] [4] [5] [6] [7] . SMA is caused by the homozygous functional loss of the survival motor neuron 1 (SMN1) gene due to deletion, subtle mutation, or gene conversion [2] [3] [4] [5] . SMN2, a nearly identical copy of SMN1, fails to compensate for SMN1 loss due to a critical C to T transition at the 6 th position (C6U in transcript) in exon 7
[8]. C6U leads to exon 7 skipping during premRNA splicing of SMN2 [9] ; as a consequence, a truncated, dysfunctional and rapidly degraded protein (SMNΔ7) is produced [10, 11] . The defects caused by SMN1 deficiency can be compensated by increased copies of SMN2, which produces low levels of full-length SMN [12] . Considering all SMA patients retain at least one functional copy of SMN2, it is reasonable to assume that strategies aimed at correcting SMN2 exon 7 splicing hold the promise for a treatment. Indeed, the postnatal increase of SMN levels through SMN2 exon 7 splicing correction-by both small compounds and antisense oligonucleotides (ASOs)-provides substantial therapeutic benefits in animal models of SMA [13] [14] [15] [16] . Several recent reviews summarized the general progress in the rapidly evolving field of oligonucleotide research [17] [18] [19] [20] [21] . This review is inspired by several independent reports in which different ASO Developing ASO-based splicing correction therapeutics is not a straight-forward task.
Splicing modulation using an ASO-mediated approach requires sequestration of a splicing cis-element [18] . Since the majority of the human genome is transcribed [22] , there is a substantial risk that an ASO could anneal to analogous sequences through mismatch base pairing and have off-target effects. 
ISS-N1 as a promising therapeutic target
To restore SMN2 exon 7 inclusion in SMA, it is essential that splice-switching ASOs target an inhibitory cis-element. It is also desirable that the inhibitory cis-element is located within an intronic sequence in order to avoid interfering with the translation and transport of mRNA.
Discovery of ISS-N1 (intronic splicing silencer N1) in 2006 provided a major breakthrough for an ASO-mediated splicing correction approach in SMA [31] . ISS-N1 is a 15-nucleotide sequence spanning the 10 th to 24 th positions of intron 7
( Figure 1A ). ISS-N1 creates a strong negative context at the 5' splice site (5' ss) of exon 7, and ISS-N1 deletion fully restores SMN2 exon 7 inclusion [31] . Remarkably, the deletion of ISS-N1 confers such a stimulatory effect on SMN2 exon 7 splicing that all known positive ciselements within exon 7 become dispensable. Therefore, ISS-N1 is described as the master checkpoint of SMN2 exon 7 splicing regulation [32] . The therapeutic efficacy of ISS-N1 was first assessed by blocking ISS-N1 using a 20-mer ASO chemistry [33] . MOE chemistry, a proprietary product of ISIS Pharmaceuticals, is considered to confer increased nuclease resistance and decrease non-specific protein interactions [34] .
The authors concluded that the stimulatory effect of ISS-N1 targeting MOE ASO was higher than other MOE ASOs targeting different regions of SMN2 [33] . They independently validated the strong inhibitory nature of ISS-N1 and generated interest in an ASO-mediated therapy for SMA. Splicing cis-elements are indicated by boxes. Numbering starts from the first position of SMN2 intron 7. Cis-elements shown here are described in detail in a recent review by Singh and Singh [9] . ISS-N1 is negative cis-element that has emerged as the leading therapeutic target for an ASO-mediated splicing correction in SMA [31] [32] [33] [50] [51] [52] 55, 60, 61] . Binding sites of inhibitory factor hnRNP A1 [33] and stimulatory factors TIA1 and TIAR [39] have been indicated. GC-rich sequence constitutes the target for splicing correction by the shortest ASO [35] . A cytosine residue at the 10 th intronic position ( 10 C) associates with a long-distance interaction (LDI) with the downstream intronic sequences [36] . Sequestration of ISS-N1 or GC-rich sequence appears to abrogate the inhibitory LDI associated with is the first and most critical step of spliceosomal assembly, which is a multistep dynamic process of intron removal [41] . Recent reports suggest U1 snRNP recruitment plays a role in regulating isoform expression and polyadenylation [42, 43] . Considering intron 7 is the last intron of SMN2, it is possible that the enhanced recruitment of U1 snRNP upon sequestration of ISS-N1 provides additional benefits unrelated to splicing.
In vivo studies with ISS-N1 targeting ASOs
The broadly for other therapies that will require delivery to the spinal cord [51] .
Encouraged by the results of ICV injections of MOE ASOs in two SMA mouse models
Translational Neuroscience [50, 51] , the Krainer group in collaboration with ISIS Pharmaceuticals performed an elaborate study using the Taiwanese type I SMA mice (two copies of SMN2), a more severe SMA mouse model [52] . This model was generated from mild Taiwanese SMA mice and has a median lifespan of ~10 days [56, 57] . The major finding of this study was an unexpectedly high efficacy of ASO-10-27 when delivered peripherally [52] . The animals tolerated a very high dose of subcutaneously (SC) administered ASO-10-27. The best survival outcome was observed when animals received two SC administrations (one at P0-P1 and the other at P2-P3) each at 160 µg/g body weight [52] .
The median life expectancy of treated mice increased ~25 fold (from ~10 days to ~273 days). 
In vivo studies with ISS-N1 targeting morpholinos
Phosphorodiamidate morpholino oligomers 
In vivo studies with ISS-N1 targeting bifunctional ASOs
Bifunctional ASOs anneal to specific RNA sequences and recruit additional factors through hanging tails [62] . and in SMA mice [65] [66] [67] [68] . Blocking the 3' ss of exon 8 by an ASO embedded in U7 snRNAs was shown to prevent exon 7 skipping and increase SMN levels in SMA patient-derived cells [69] .
These results underscore that the transcripts retaining SMN2 intron 7 are capable of being polyadenylated, exported out of the nucleus, and translated in the cytoplasm. Recently, an 8-mer ASO (3UP8) that sequesters a GC-rich sequence within intron 7 was shown to have a strong stimulatory effect on SMN2 exon 7 inclusion in SMA patient fibroblast cell lines [35, 70] . In addition to being cost effective, small
ASOs offer the advantage of being less tolerant towards non-canonical and mismatch base pairing, a major cause for the nonspecific effect associated with large ASOs. Consistently, 3UP8
showed zero tolerance for a single mismatch base pair mutation at the target site [35] .
However, it remains to be seen whether the Translational Neuroscience expected benefit of a small ASO is realized in a mouse model of SMA. 
Conclusions and future directions

